Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels-Reference-Cited by-同舟云学术

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels

Published:2018-07-20 Issue:9 Volume:32 Page:2028-2031
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Pavlasova Gabriela,Borsky Marek,Svobodova Veronika,Oppelt Jan,Cerna Katerina,Novotna Jitka,Seda Vaclav,Fojtova Miloslava,Fajkus Jiri,Brychtova Yvona,Doubek Michael,Pospisilova Sarka,Mayer Jiri,Mraz Marek

Funder

Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic)

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0211-0.pdf

Reference15 articles.

1. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635–42.

2. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+conductance found constitutively in B lymphocytes. J Cell Biol. 1993;121:1121–32.

3. Morsy DED, Sanyal R, Zaiss AK, Deo R, Muruve DA, Deans JP. Reduced T-dependent humoral immunity in CD20-deficient mice. J Immunol. 2013;191:3112–18.

4. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IAM, Dolman KM, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120:214–22.

5. Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016;128:1609–13.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs;Leukemia;2024-06-14

2. Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion;Cellular Oncology;2024-04-25

3. B cell receptor signaling proteins as biomarkers for progression of CLL requiring first-line therapy;Leukemia & Lymphoma;2024-04-15

4. Role of CD20+ T cells in cancer, autoimmunity and obesity;Journal of Endocrinology;2024-01-18

5. Anti-CD20 antibody treatment for B-cell malignancies;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024